Fostemsavir (BioDeep_00000179213)

   

human metabolite blood metabolite


代谢物信息卡片


({3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methoxy)phosphonic acid

化学式: C25H26N7O8P (583.1580406)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 92.86%

分子结构信息

SMILES: CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC
InChI: InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)

描述信息

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors

同义名列表

6 个代谢物同义名

({3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methoxy)phosphonic acid; (3-((4-Benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo(2,3-c)pyridin-1-yl)methyl dihydrogen phosphate; ({3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methoxy)phosphonate; {3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl}methoxyphosphonic acid; BMS-663068FOSTEMSAVIR; Fostemsavir



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrobial agents and chemotherapy. 2022 04; 66(4):e0225121. doi: 10.1128/aac.02251-21. [PMID: 35315687]
  • Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants. HIV research & clinical practice. 2021 12; 23(1):1-8. doi: NULL. [PMID: 35285786]
  • Daniel A Hussar. New Drugs 2021, Part 2. Nursing. 2021 Oct; 51(10):18-29. doi: 10.1097/01.nurse.0000791756.56705.dd. [PMID: 34580258]
  • Mindy Magee, Jill Slater, Frank Mannino, Peter Ackerman, Cyril Llamoso, Katy Moore. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. Journal of clinical pharmacology. 2021 07; 61(7):939-953. doi: 10.1002/jcph.1810. [PMID: 33368327]
  • Max Lataillade, Jacob P Lalezari, Michael Kozal, Judith A Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean-Michel Molina, Santiago Moreno, Beatriz Grinsztejn, Ricardo S Diaz, Antonella Castagna, Princy N Kumar, Gulam H Latiff, Edwin De Jesus, Marcia Wang, Shiven Chabria, Margaret Gartland, Amy Pierce, Peter Ackerman, Cyril Llamoso. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. The lancet. HIV. 2020 11; 7(11):e740-e751. doi: 10.1016/s2352-3018(20)30240-x. [PMID: 33128903]
  • Francesco Saladini, Alessia Giannini, Federica Giammarino, Franco Maggiolo, Francesca Vichi, Giulio M Corbelli, Andrea Galli, Alba Bigoloni, Andrea Poli, Maria M Santoro, Maurizio Zazzi, Antonella Castagna. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. The Journal of antimicrobial chemotherapy. 2020 09; 75(9):2547-2553. doi: 10.1093/jac/dkaa178. [PMID: 32464638]
  • Chakradhar Lagishetty, Katy Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis. Clinical and translational science. 2020 07; 13(4):769-776. doi: 10.1111/cts.12763. [PMID: 32027457]
  • Katy Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin, Elsa Myers, Peter Ackerman, Cyril Llamoso. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants. British journal of clinical pharmacology. 2019 08; 85(8):1771-1780. doi: 10.1111/bcp.13964. [PMID: 30980734]
  • Tao Wang, Yasu Ueda, Zhongxing Zhang, Zhiwei Yin, John Matiskella, Bradley C Pearce, Zheng Yang, Ming Zheng, Dawn D Parker, Gregory A Yamanaka, Yi-Fei Gong, Hsu-Tso Ho, Richard J Colonno, David R Langley, Pin-Fang Lin, Nicholas A Meanwell, John F Kadow. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir. Journal of medicinal chemistry. 2018 07; 61(14):6308-6327. doi: 10.1021/acs.jmedchem.8b00759. [PMID: 29920093]
  • Pedro Cahn, Valeria Fink, Patricia Patterson. Fostemsavir: a new CD4 attachment inhibitor. Current opinion in HIV and AIDS. 2018 07; 13(4):341-345. doi: 10.1097/coh.0000000000000469. [PMID: 29771694]
  • Li Zhu, Matthew Hruska, Carey Hwang, Vaishali Shah, Michael Furlong, George J Hanna, Richard Bertz, Ishani Savant Landry. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects. Antimicrobial agents and chemotherapy. 2015 Jul; 59(7):3816-22. doi: 10.1128/aac.04914-14. [PMID: 25870057]
  • Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, Betsy Eggers, Hua Fang, Li Fan, Matthew Healy, David R Langley, Carey Hwang, Max Lataillade, George J Hanna, Mark Krystal. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. The Journal of antimicrobial chemotherapy. 2014 Mar; 69(3):573-81. doi: 10.1093/jac/dkt412. [PMID: 24128669]
  • Neelanjana Ray, Carey Hwang, Matthew D Healy, Jeannette Whitcomb, Max Lataillade, Megan Wind-Rotolo, Mark Krystal, George J Hanna. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. Journal of acquired immune deficiency syndromes (1999). 2013 Sep; 64(1):7-15. doi: 10.1097/qai.0b013e31829726f3. [PMID: 23614999]
  • Richard E Nettles, Dirk Schürmann, Li Zhu, Michele Stonier, Shu-Pang Huang, Ih Chang, Caly Chien, Mark Krystal, Megan Wind-Rotolo, Neelanjana Ray, George J Hanna, Richard Bertz, Dennis Grasela. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. The Journal of infectious diseases. 2012 Oct; 206(7):1002-11. doi: 10.1093/infdis/jis432. [PMID: 22896665]